UK’s NHS Cites Significant Savings From Generics And Biosimilars
A Third Of £1.2bn Total Over Three Years Came From Adalimumab, NHS Reveals
Savings made through the use of generics and biosimilars have been highlighted by the UK’s NHS, with the organization pointing to savings of £1.2bn over three years, a third of which came from Humira biosimilars alone.
You may also be interested in...
In the second part of an exclusive interview with Generics Bulletin, BGMA chief executive Mark Samuels talks about the UK’s new biosimilars licensing pathway, future trade deals and IP, and efforts around repurposing generics, as well as looking ahead to how the UK’s vaccination program could reshape the COVID-19 pandemic.
Licensing new uses of existing medicines has several benefits over off-label use, such as offering assurances that the indication is evidence based and subject to an ongoing safety monitoring program, according to a new report.
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.